Patient-Based Therapeutics

AcuraStem is a near-to-clinic, patient-based, biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

get to know us

Patient Focused

rp3.jpgrp1.jpgrp2.jpg

rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 


learn about our work

Neurodegenerative Disease Areas

Latest News

May 29, 2023

AcuraStem’s Sam Alworth Onsite at #BIO2023

Join AcuraStem's CEO, Sam Alworth, at the forthcoming 2023 BIO International Convention in Boston from June 5-8, 2023. AcuraStem is at the cutting edge of developing treatments for neurodegenerative diseases, including sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

» Read more
April 10, 2023

AcuraStem CEO Sam Alworth to Present on PIKFYVE for FTD at ADDF's Defeating Dementia Symposium

AcuraStem's CEO, Sam Alworth, is set to present on the company’s latest advances in the development of a PIKFYVE antisense oligonucleotide (ASO) therapeutic for diverse forms of FTD (FTD) at the Alzheimer's Drug Discovery Foundation's (ADDF) Defeating Dementia Symposium on April 13.

» Read more
March 20, 2023

BioSpace Highlights the Progress of AcuraStem’s Antisense Oligonucleotide Targeting PIKFYVE and a New Program Targeting SYF2 in Preclinical Studies

AcuraStem’s progress in advancing an antisense oligonucleotide (ASO) targeting PIKFYVE and development of therapeutic candidates targeting SYF2 in preclinical studies has been featured in a newly posted BioSpace article.

» Read more

Keep Up to Date with AcuraStem